HFGB was already the leading supplier of "rutin" in China & has been filling huge order increases for that product & "diosmin" from new & expanded contracts from Europe.
This acquisition is not only acretive to eps but adds needed manufactoring capacity at a time it is trying to fill its backlog.
Since cashflow & pps is not high enough presently to complete HFGB's mission of becoming a much bigger full pharm.
The company is doing a good job of getting the best results from the present situation.
Smart management is adapting to reasonable & affordable ways to grow the company.[notice the shares were not only accepted @$0.70 when the current pps was $0.55 but they are restricted from trading those shares for 1 year.]
News 
Market Data 
Discover 
AI
